FDA suggests 2-mm beads to thwart chewers; DDN commits to the cold;

> Unintentional bead chewing may affect pharmacokinetics, so FDA suggests a maximum of two-millimeter beads in modified-release treatments formulated for sprinkle delivery. Draft guidance

> Channel management specialist DDN has added 140,000 square feet of temperature-controlled space, bringing its total Memphis footprint to one-half million. DDN release

> Morphotek is half way to completing its 60,000-square-foot pilot manufacturing plant for trial drugs; October is the targeted finish date. Article

> Belgian Manuel Calvelo has pleaded guilty in U.S. district court in Kansas to running an Internet pharmacy that sold $1.4 million worth of misbranded and counterfeit drugs. Article

> International law firm King & Spalding announces that former FDA official Steven Niedelman has joined the company's Washington, D.C., office as lead quality systems and compliance consultant. King & Spalding release

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.